Literature DB >> 34431465

Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports.

Konstantinos G Kyriakoulis1, Anastasios Kollias1, Ioannis G Kyriakoulis2, Ioanna A Kyprianou3, Chrysso Papachrysostomou4, Panagiotis Makaronis4, Rafail A Kotronias5, Dimitrios Terentes-Printzios6, Ioannis Toskas7, Dimitri P Mikhailidis8.   

Abstract

BACKGROUND: Venous Thromboembolism (VTE) is common among patients with severe Coronavirus Disease 2019 (COVID-19). Anticoagulation in hospitalized COVID-19 patients has been associated with survival benefit; however, the optimal thromboprophylaxis strategy has not yet been defined.
OBJECTIVE: To identify published guidance reports by national and international societies regarding thromboprophylaxis strategies in COVID-19 patients in different settings (outpatients, hospitalized, post-discharge).
METHODS: A systematic review of the literature (Pubmed/EMBASE) was conducted independently by two investigators.
RESULTS: Among 1942 initially identified articles, 33 guidance documents were included: 20 published by national and 13 by international societies. These documents provide recommendations mainly for hospitalized (97% of reports) and post-discharge (75%) COVID-19 patients, and less so for outpatients (34%). Thrombotic and bleeding risk stratification prior to any treatment decision is the cornerstone of all suggested thromboprophylaxis strategies; 81% of the documents recommend thromboprophylaxis for all hospitalized patients with a prophylactic dosage of low molecular weight heparin irrespective of VTE risk. Intermediate or therapeutic dose intensity is recommended in high VTE risk patients by 56% and 28% of documents, respectively. Mechanical thromboprophylaxis is suggested in case of high bleeding risk or contraindication to pharmacological thromboprophylaxis (59% of documents). Extended pharmacological thromboprophylaxis is recommended for patients with high VTE risk after hospital discharge (63% of documents). For non-hospitalized outpatients, 28% of documents recommend pharmacological thromboprophylaxis for high VTE risk.
CONCLUSION: The current guidance identifies thromboprophylaxis in COVID-19 patients, especially during hospitalization, as of major importance for the prevention of VTE. Recommendations are derived from limited evidence from observational studies. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Anticoagulation; COVID-19; deep vein thrombosis; guidelines; pulmonary embolism; thromboprophylaxis; venous thromboembolism.

Mesh:

Substances:

Year:  2022        PMID: 34431465     DOI: 10.2174/1570161119666210824160332

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  2 in total

Review 1.  High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Anastasios Kollias; Konstantinos G Kyriakoulis; Ioannis P Trontzas; Vassiliki Rapti; Ioannis G Kyriakoulis; Christina A Theochari; Evangelos Dimakakos; Garyphallia Poulakou; Konstantinos Syrigos
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

Review 2.  Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine.

Authors:  Peter Kubatka; Alena Mazurakova; Lenka Koklesova; Marek Samec; Juraj Sokol; Samson Mathews Samuel; Erik Kudela; Kamil Biringer; Ondrej Bugos; Martin Pec; Barbara Link; Marian Adamkov; Karel Smejkal; Dietrich Büsselberg; Olga Golubnitschaja
Journal:  EPMA J       Date:  2022-08-15       Impact factor: 8.836

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.